Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons to Give a Big Hooray for Tilray After Its Q4 Update

By Keith Speights - Feb 18, 2021 at 6:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Canadian cannabis producer delivered a much-improved performance.

Tilray (TLRY) has given investors plenty to cheer about so far this year. Its share price has more than quadrupled partly due to excitement about the pending merger with Aphria (APHA). However, Tilray's business performance hasn't been so great in recent quarters. Until now. 

The Canadian cannabis producer announced its fourth-quarter results following the market close on Wednesday. The marijuana stock soared 9% in after-hours trading. Here are three reasons to applaud Tilray after its Q4 update.

Three pairs of hands clasped together.

Image source: Getty Images.

1. Rebounding revenue

In the third quarter of 2020, Tilray reported flat overall revenue compared to the prior-year period. Its cannabis revenue even fell 11% year over year. The company's performance in Q4 was much better. 

Tilray announced total Q4 revenue of $56.6 million, a 20.5% year-over-year jump and a 10% quarter-over-quarter increase. Importantly, the company's cannabis revenue soared 46% year over year to $41.2 million. That growth was driven by 191% higher international medical cannabis sales and 49% higher Canadian adult-use recreational marijuana sales.

The only fly in the ointment was hemp segment revenue, which fell 18% year over year to $15.3 million. Tilray attributed this decline to a large customer shifting to a private-label product along with changes in consumer shopping patterns due to the COVID-19 pandemic.

2. Improving gross margin

Tilray's gross margin in the third quarter was a paltry 7%. But the cannabis producer's gross margin jumped to 29% in the fourth quarter. The year-over-year comparison looked even better -- Tilray's gross margin in Q4 of 2019 was negative 121%.

The company's higher revenue helped improve Tilray's gross margin. However, the main difference was a significantly lower cost of sales in Q4. There was good and bad news with Tilray's increased gross margin, though.

The good news is that the company recorded much lower inventory valuation adjustments than it did in the prior-year period. This pulled its cost of sales down a lot. The bad news is that Tilray's average cannabis net cost per gram rose year over year. This increase stemmed mainly from the company's discontinuation of bulk sales and, to a lesser extent, from greater sales of cannabis derivative products, which have higher costs than dried flower.

3. Stronger adjusted EBITDA

Arguably the best news of all for Tilray in the fourth quarter was its positive trend for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). Tilray delivered on its goal of achieving positive adjusted EBITDA in Q4. 

The company posted Q4 adjusted EBITDA of $2.2 million. In the fourth quarter of 2019, the company had an adjusted EBITDA loss of $35.3 million. Tilray substantially improved in the third quarter of 2020, but still reported an adjusted EBITDA loss of $1.5 million.

Solid revenue growth tends to pull EBITDA up. Tilray's rebounding revenue helped considerably. However, the company's major cost-cutting initiatives also enabled it to meet its objective of generating positive adjusted EBITDA.

One final hurrah to come?

Tilray could have one more quarter to report in its current form. The pending merger between it and Aphria is expected to close in the second quarter of 2021. The combined entity will still use the Tilray name. But the company will look much different after the merger with Aphria.

Aphria shareholders will own the majority of the combined company (62%). Current Aphria chairman and CEO Irwin Simon will hold those same positions in the post-merger organization. Aphria will have seven seats on the board of directors compared to only two current Tilray directors plus a new director to be named. In reality, the "new" Tilray will be more Aphria than Tilray. 

Tilray deserves the hoorays for its Q4 update. But, in a real sense, the company could only have one final hurrah on the way.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.